Results 31 to 40 of about 1,261,128 (384)
Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis [PDF]
, 2018 Background. The knowledge of natural history of patients with portal hypertension (PH) not due to cirrhosis is less well known than that of cirrhotic patients. Aim.
Aprile, Francesca +7 more
core +1 more source
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS
Hepatology, EarlyView., 2022 The river diagram demonstrates that after transjugular intrahepatic portosystemic shunt insertion (TIPS) the majority of patients without ascites and 50% of the patients with ascites detectable at ultrasound, show the best response in the long term follow‐up.
Alexander Queck +14 more
wiley +1 more source
Nonalcoholic fatty liver disease and portal hypertension.
Exploration of Medicine, 2020 Nonalcoholic fatty liver disease (NAFLD) is a substantial and growing problem worldwide and has become the second most common indication for liver transplantation as it may progress to cirrhosis and develop complications from portal hypertension ...
M. Ryou, N. Stylopoulos, G. Baffy
semanticscholar +1 more source
A community of portal hypertension [PDF]
Hepatology International, 2021 Portal hypertension is an important, if not the most important, factor affecting the clinical course of patients with cirrhosis, as it can predict the development of cirrhosis-related complications, such as variceal bleeding, ascites, and hepatic encephalopathy [1,2,3].
Qi, X, Huang, Y, Pavlides, M, Rockey, DC
openaire +3 more sources
Hepatology, EarlyView., 2022 A deleterious variant of FCHSD1 results in mTOR pathway overactivation and may cause porto‐sinusoidal vascular disorder (PSVD). The pedigree of the family demonstrated an autosomal dominant disease with variable expressivity. Whole‐genome sequencing and Sanger sequencing both validated the existence of the FCHSD1 variant and the heterozygosity of c ...
Jingxuan Shan +19 more
wiley +1 more source
Paediatrica Indonesiana, 2017 A case of portal hypertension in a 9-year-old Indonesian female child is presented. The diagnosis was made by demonstrating oesophageal vanices radiologically and surgically, and by measuring the portal venous pressure. Portocaval side to side shunt was done resulting in diminishing of the oesophageal varices, disappearance of hypersplenism, and a ...
I D, Arif, M, Said, E M, Halimun
openaire +2 more sources
Amiloride reduces portal hypertension in rat liver cirrhosis [PDF]
, 2010 Objective This study aimed to investigate the effect of amiloride on portal hypertension. Amiloride is known to inhibit Na(+)/H(+) exchangers on activated hepatic stellate cells.
Beitinger, Frigga +6 more
core +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
Hepatology, EarlyView., 2022 Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study. Abstract Background and Aims Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real‐world data are lacking.
Shannon M. Vandriel +93 more
wiley +1 more source
Effect of partial portal vein ligation on hepatic regeneration [PDF]
, 1988 To evaluate the effect of portal hypertension and diminished portal venous blood flow to the liver on hepatic regeneration, male rats were subjected to partial portal vein ligation and subsequently to a two-thirds partial hepatectomy.
Bollman J L +29 more
core +1 more source